Skip to content

Ashraf Kamour

2 papers in the library · 23 citations · publishing 2014-2016

Papers

Patterns of presentation and clinical toxicity after reported use of alpha methyltryptamine in the United Kingdom. A report from the UK National Poisons Information Service

Clinical Toxicology February 28, 2014 Ashraf Kamour, David A. James, Robert Spears et al. 23 citations

Acute toxicity from recreational use of alpha methyltryptamine (AMT) in the UK, reported to the National Poisons Information Service from March 2009 to September 2013, involved 63 telephone enquiries, mostly in 2011 and 2012. Most patients were male (68%) with a median age of 20 years; ingestion was the most common route. Compared to mephedrone users, AMT users more frequently experienced acute mental health disturbances (66% vs. 32%), stimulant effects (66% vs. 40%), and seizures (14% vs. 2%). Toxicity from AMT has been encountered since January 2011, though still infrequent.

Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study.

Clinical toxicology (Philadelphia, Pa.) September 1, 2016 Simon L Hill, Javad Najafi, Michael Dunn et al.

In seven men who presented to hospitals in England between July and October 2015 after smoking 'legal high' products, analytically confirmed exposure to the synthetic cannabinoid receptor agonist MDMB-CHMICA was associated with acidosis (respiratory in three, metabolic in three, mixed in one), reduced level of consciousness (six of seven), dilated pupils (five of seven), fast heart rate (five of seven), slow heart rate (two of seven), convulsions (two of seven), and agitation (three of seven). Recovery occurred within 24 hours in all but one case where methiopropamine was also present.